Hepatitis C News and Research

Latest Hepatitis C News and Research

Securing universal access to HIV prevention, care, treatment and support

The biennial meeting of the global AIDS community concluded today with clear evidence of tangible progress in HIV research and programme scale up, yet facing an urgent need for increased resources, the protection of human rights, and broader use of scientifically sound prevention strategies. Delegates and organizers depart Vienna - where the conference opened 18 July under the theme of Rights Here, Right Now -- with a renewed commitment to push for securing universal access to HIV prevention, care, treatment and support.

23 Jul 2010

Vienna Declaration signed to support evidence-based drug policy for improving community health

Sandra Roelofs, First Lady of Georgia; George Tsereteli, Georgia's Deputy Chairman of Parliament; and Irakli Giorgobiani, Georgia's Vice Minister of Labour, Health and Social Affairs, today signed the Vienna Declaration, the official declaration of the XVIII International AIDS conference in Vienna, Austria.

23 Jul 2010

New model for scaling up treatment, prevention of HIV amongst IDUs

Against the backdrop of some of the globe's fastest growing HIV epidemics in Eastern Europe and Central Asia, a report launched today at the XVIII International AIDS conference in Vienna makes the case for a new model for scaling up treatment and prevention of HIV amongst Injecting Drug Users.

23 Jul 2010

Early HAART during TB treatment prolongs survival of untreated HIV-infected adults: CAMELIA study

A clinical trial in Cambodia has found it possible to prolong the survival of untreated HIV-infected adults with very weak immune systems and newly diagnosed tuberculosis (TB) by starting anti-HIV therapy two weeks after beginning TB treatment, rather than waiting eight weeks, as has been standard.

23 Jul 2010

NVHR releases statement on New York Times article 'Hope against Hepatitis C'

In response to today's New York Times article, "Hope against Hepatitis C," Andrew Muir, M.D., M.H.S., Director, Gastroenterology/Hepatology Research, Duke Clinical Research Institute and Steering Committee Member of the National Viral Hepatitis Roundtable (NVHR) released the following statement:

23 Jul 2010

Independent DSMB recommends Inhibitex to complete FV-100 Phase II clinical trial for shingles

Inhibitex, Inc. today announced that the independent data safety monitoring board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with complete 30-day follow-up safety data on the third quartile (75%) of the patients that the Company plans to enroll in the trial. Based upon its review, the DSMB recommended that the trial continue to completion without modification.

23 Jul 2010

Human Genome Sciences second-quarter revenues increase to $38.8 million

Human Genome Sciences, Inc. today announced financial results for the quarter ended June 30, 2010, and provided highlights of recent key developments.

23 Jul 2010

Reusing syringes in anesthesia leads to viral transmission: Study

Hepatitis B virus and hepatitis C virus can be transmitted during intravenous administration of anesthesia, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute. In this study, doctors found that anesthesia contamination - not endoscopy contamination - was the cause of infection.

23 Jul 2010

Achillion nominates ACH-2928 NS5A clinical candidate for treatment of HCV

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced the nomination of a lead clinical candidate in its fourth proprietary program against hepatitis C virus (HCV) infection. The candidate, ACH-2928, is an NS5A inhibitor that in preclinical studies has demonstrated excellent potency against HCV RNA replication, as well as good pharmacokinetic and safety profiles.

22 Jul 2010

Abbott second-quarter global sales increase 17.8% to $8.8 billion

Abbott today announced financial results for the second quarter ended June 30, 2010.

21 Jul 2010

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

AiCuris announced today publication of preclinical data on AIC246, at the International Herpesvirus Workshop in Salt Lake City, Utah, USA from 24 – 29 July 2010. AIC246 is a novel anti-HCMV drug currently in clinical phase 2 testing.

21 Jul 2010

ATLIS 2010 shows gap in patient-physician dialogue that may negatively impact patients' quality of life

Results from the landmark AIDS Treatment for Life International Survey, a multi-country survey of more than 2,000 people living with HIV/AIDS, revealed a significant gap in patient-physician dialogue about critical health-related conditions that may negatively impact patients' overall long-term health, quality of life, and treatment outcomes.

21 Jul 2010

UDCA fails to improve overall histology in NASH patients: Study

A study conducted by researchers at Johann Wolfgang Goethe University in Frankfurt, Germany found that high doses of ursodeoxycholic acid, suggested by some studies to have a beneficial effect on nonalcoholic steatohepatitis, does not improve overall histology in these patients. Full findings of this study are published in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

21 Jul 2010

Depressive symptoms in patients with HCV infection overlooked

Researchers from Denmark, Sweden, Norway and Finland (the NORDynamIC project group) have observed that depressive symptoms in patients with hepatitis C virus (HCV) infection are commonly overlooked in routine clinical interviews, and that treatment-induced depression compromises the outcome of HCV therapy. A second U.S. study found that patients with chronic infection had lower (work) productivity and incurred higher medical benefit costs than those without HCV.

21 Jul 2010

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2010. Total revenues for the second quarter of 2010 were $1.93 billion, up 17 percent compared to total revenues of $1.65 billion for the second quarter of 2009. Net income for the second quarter of 2010 was $712.1 million, or $0.79 per diluted share, compared to net income for the second quarter of 2009 of $571.4 million, or $0.61 per diluted share.

21 Jul 2010

NanoViricides presents study results of nanoviricides anti-Ebola agents

NanoViricides, Inc. reports that the results of the evaluation of several of its nanoviricides anti-Ebola agents were presented July 17th at the Annual Meeting of the American Society for Virology, July 17-21, at Montana State University, Bozeman, MT. Dr. Corinne Scully delivered the presentation, which was entitled "Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection."

20 Jul 2010

AIDS 2010 studies, releases: Treating HIV-positive patients with ARVs drove down number of new HIV infections, study finds

"Treating HIV patients with cocktails of AIDS drugs helps to stop them spreading the infection further and more than halved the number of new HIV diagnoses in a study in Canada, scientists said on Sunday," Reuters reports.

20 Jul 2010

Abortion fight again heats up over high-risk pools, other health reform news

Anti-abortion activists have "scored a victory" after a decision last week by the Obama administration to not allow the new high-risk pools in America to cover most abortions, The Associated Press reports.

20 Jul 2010

A look into HIV related issues

According to a report from US health officials, the poorer neighborhoods of America's cities harbour at least 1 in 50 heterosexual adults infected with HIV. These figures are more than elsewhere in the country. According to the research team from the U.S. Centers for Disease Control and Prevention (CDC), being poor and getting HIV are linked and this was regardless of race or ethnicity.

19 Jul 2010

Study evaluates immunization benefits of dissolving microneedles

A new vaccine-delivery patch based on hundreds of microscopic needles that dissolve into the skin could allow persons without medical training to painlessly administer vaccines - while providing improved immunization against diseases such as influenza.

19 Jul 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Securing universal access to HIV prevention, care, treatment and support

Vienna Declaration signed to support evidence-based drug policy for improving community health

New model for scaling up treatment, prevention of HIV amongst IDUs

Early HAART during TB treatment prolongs survival of untreated HIV-infected adults: CAMELIA study

NVHR releases statement on New York Times article 'Hope against Hepatitis C'

Independent DSMB recommends Inhibitex to complete FV-100 Phase II clinical trial for shingles

Human Genome Sciences second-quarter revenues increase to $38.8 million

Reusing syringes in anesthesia leads to viral transmission: Study

Achillion nominates ACH-2928 NS5A clinical candidate for treatment of HCV

Abbott second-quarter global sales increase 17.8% to $8.8 billion

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

ATLIS 2010 shows gap in patient-physician dialogue that may negatively impact patients' quality of life

UDCA fails to improve overall histology in NASH patients: Study

Depressive symptoms in patients with HCV infection overlooked

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

NanoViricides presents study results of nanoviricides anti-Ebola agents

AIDS 2010 studies, releases: Treating HIV-positive patients with ARVs drove down number of new HIV infections, study finds

Abortion fight again heats up over high-risk pools, other health reform news

A look into HIV related issues

Study evaluates immunization benefits of dissolving microneedles

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in